SAN FRANCISCO (AP) 鈥� SAN FRANCISCO (AP) 鈥� Nektar Therapeutics (NKTR) on Thursday reported a loss of $44.9 million in its first quarter.
The San Francisco-based company said it had a loss of $1.82 per share.
The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.74 per share.
The biopharmaceutical company posted revenue of $10.9 million in the period, also missing Street forecasts. Six analysts surveyed by Zacks expected $11.4 million.
_____
This story was generated by (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a at https://www.zacks.com/ap/NKTR
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
